CD8A and breast cancer: Specifically, consistent with the fact that BCs overexpressing the Neu proto-oncogene display high VEGF levels, the combination of DC101 with Neu-specific vaccination accelerates tumor regression in murine models of BC by augmenting the cytotoxic activity of CD8+ T cells [129].